Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
CONTEXT: Meta-analyses of clinical studies have suggested an increased incidence of peripheral fractures in postmenopausal women with type 2 diabetes mellitus taking pioglitazone. The mechanism behind this apparent increase is unknown. OBJECTIVE: The objective of the study was to examine the effects of pioglitazone on bone mineral density (BMD) and turnover. DESIGN AND SETTING: Twenty-five sites (in the United States) enrolled participants in this randomized, double-blind, placebo-controlled study. PARTICIPANTS: Postmenopausal women (n = 156) with impaired fasting glucose or impaired glucose tolerance participated in the study. INTERVENTIONS: The intervention consisted of pioglitazone 30 mg/d (n = 78) or placebo (n = 78), increased to 45 mg/d after 1 month, for 12 months of treatment total, followed by 6 months of washout/follow-up. MAIN OUTCOME MEASURES: Percentage changes from baseline to month 12 and from month 12 to month18 in BMD in total proximal femur (primary end point), total body, femoral neck, lumbar spine, and radius were measured. RESULTS: Least squares mean changes from baseline to month 12 in total proximal femur BMD were -0.69% for pioglitazone and -0.14% for placebo (P = .170). No statistically significant between-group differences were observed for any BMD or bone remodeling marker end point. We observed improved glycemic control and insulin sensitivity with pioglitazone treatment. In addition, pioglitazone appeared to increase body fat, which may affect bone density measurements, especially in the lumbar spine. One pioglitazone-treated and three placebo-treated women experienced confirmed fractures. Over 18 months, one pioglitazone-treated (1.3%) and eight placebo-treated women (10.3%) developed overt type 2 diabetes mellitus. The pattern and incidence of adverse events with pioglitazone were consistent with clinical experience with thiazolidinediones. CONCLUSIONS: Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mechanism is uncertain, and studies have not shown a consistent effect of the drug on bone density.44,45”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [45]
Citations
Cites
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & Canalis, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 914
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
PPAR-γ regulates osteoclastogenesis in mice
Wan, Y., Chong, L.-W., & Evans, R. M. (2007) · Nature Medicine · doi:10.1038/nm1672 · Cited by 517
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka-Czernik, B. (2004) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 454
Cited by
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
“Bone HG [12] 2013 Postmenopausal women with impaired fasting glucose or impaired glucose tolerance 59 Pioglitazon vs placebo”
Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
Paschou, S. Α., Dede, A. D., Anagnostis, P. G., Vryonidou, A., Morganstein, D., & Goulis, D. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00042 · Cited by 205
Effects of diabetes drugs on the skeleton
Meier, C., Schwartz, A. V., Egger, A., & Lecka-Czernik, B. (2016) · Bone · doi:10.1016/j.bone.2015.04.026 · Cited by 174
Sweeney, T. E., & Morton, J. M. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.016 · Cited by 120
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 112
Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
“Most (5), but not all (28), studies examining serial bone mineral density by dual x-ray absorptiometry have found modest bone loss.”
BackgroundOral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
Palermo, A., D’Onofrio, L., Eastell, R., Schwartz, A. V., Pozzilli, P., & Napoli, N. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3123-0 · Cited by 114
Diabetes pharmacotherapy and effects on the musculoskeletal system
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I., & Thrailkill, K. M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 100
The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes
Napoli, N., Strollo, R., Paladini, A., Briganti, S., Pozzilli, P., & Epstein, S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/690783 · Cited by 110
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, A. V., Chen, H., Ambrosius, W. T., Sood, A., Josse, R. G., Bonds, D. E., Schnall, A. M., Vittinghoff, E., Bauer, D. C., Banerji, M. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1215 · Cited by 85
Chiu, C., Du, Y., Ou, H., & Beverly, E. A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s53482 · Cited by 78
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 75
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Adil, M., Khan, R. A., Kalam, A., Venkata, S. K., Kandhare, A. D., Ghosh, P., & Sharma, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.008 · Cited by 75
Bone Quality and Fracture-Healing in Type-1 and Type-2 Diabetes Mellitus
Henderson, S., Ibe, I. K., Cahill, S. V., Chung, Y. H., & Lee, F. Y. (2019) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.18.01297 · Cited by 57
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Viscoli, C. M., Kernan, W. N., & Young, L. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605904 · Cited by 50
Therapeutic strategies for type 2 diabetes mellitus in women after menopause
Paschou, S. Α., Marina, L., Spartalis, E. D., Anagnostis, P. G., Alexandrou, A. P., Goulis, D. G., & Lambrinoudaki, I. V. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.05.003 · Cited by 49
Diabetes Drug Effects on the Skeleton
Chandran, M. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0203-x · Cited by 48
Portillo‐Sanchez, P., Bril, F., Lomonaco, R., Barb, D., Orsak, B., Bruder, J. M., & Cusi, K. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12833 · Cited by 43
Grey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0793 · Cited by 43
Safety of Antidiabetic Therapies on Bone
Lecka‐Czernik, B. (2012) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-012-9129-7 · Cited by 43
Impact of pioglitazone on bone mineral density and bone marrow fat content
Pop, L. M., Lingvay, I., Yuan, Q., Li, X., ADAMS-HUET, B. A., & Maalouf, N. M. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4164-3 · Cited by 38
Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats
Eom, Y. S., Gwon, A., Kwak, K. M., Kim, J., Yu, S. H., Lee, S., Kim, Y. S., Park, I. B., Kim, K., Lee, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168569 · Cited by 30
Lim, S. K., Kim, K. M., Kim, S. G., Kim, D. M., Woo, J., Chung, C. H., Ko, K. S., Park, J. H., Park, Y., Kim, S. J., et al. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.377 · Cited by 27
Ipsen, E. Ø., Madsen, K. S., Chi, Y., Pedersen-Bjergaard, U., Richter, B., Metzendorf, M.-I., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013516.pub2 · Cited by 23
Prasad, T. N., Arjunan, D., Pal, R., & Bhadada, S. K. (2023) · Indian Journal of Orthopaedics · doi:10.1007/s43465-023-01049-4 · Cited by 16
Azhari, H. F., & Dawson, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1357309 · Cited by 16
Sport intensif et troubles du cycle chez la jeune femme : retentissement sur la masse osseus
Maïmoun, L., Paris, F., Coste, O., & Sultan, C. (2016) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2016.09.001 · Cited by 16
Lee, D. Y., Hwang, B. S., Choi, P., Kim, T., Kim, Y.-S., Song, B. G., Yamabe, N., Hwang, G. S., Kang, K. S., & Ham, J. (2019) · Biomolecules · doi:10.3390/biom9080335 · Cited by 14
Kim, K. M., Jin, H.-J., Lee, S. Y., Maeng, H. J., Lee, G. Y., Oh, T. J., Choi, S. H., Jang, H. C., & Lim, S. K. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.3.389 · Cited by 12
Clinical Update on Nursing Home Medicine: 2014
Messinger‐Rapport, B. J., Gammack, J. K., Little, M. O., & Morley, J. E. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.09.001 · Cited by 9
Adverse skeletal effects of drugs – beyond Glucocorticoids
O’Sullivan, S., & Grey, A. B. (2014) · Clinical Endocrinology · doi:10.1111/cen.12549 · Cited by 9
Grey, A. B. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0250-z · Cited by 6
Pharmakogene Osteoporose jenseits von Kortison: Protonenpumpenhemmer, Glitazone, Diuretika
Kann, P. H., Hadji, P., & Bergmann, R. (2014) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-013-1286-7 · Cited by 6
Pioglitazone Therapy Decreases Bone Mass Density and Increases Fat Mass: A Meta-Analysis
Zuo, L., Wang, J., Zhang, N., & Wang, J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190920123129 · Cited by 5
Filipova, E. P., Uzunova, K. H., & Vekov, T. Y. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0059-7 · Cited by 4
Bone metabolism in diabetes mellitus: focus on vitamin K2
Михайлович, Р. Ф., & Каронова, Т. Л. (2022) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12929 · Cited by 3
Insulin, Other Hypoglycemic Drugs, and Glucagon
Escaño, A. K. (2015) · Side effects of drugs annual · doi:10.1016/bs.seda.2015.05.006 · Cited by 3
Impact of Anti-hyperglycemic Medications on Bone Health
Maalouf, N. M. (2015) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9176-y · Cited by 2
Davidson, M. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22317 · Cited by 2
Sun, T., Yan, T., Zhao, Y. M., & Anjin, C. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001116 · Cited by 1
Bone and Rheumatic Disorders in Diabetes
Grey, A. B., & Dalbeth, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch59 · Cited by 1
Safety of Antidiabetic Therapies on Bone
Lecka‐Czernik, B., & Schwartz, A. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-16402-1_7
Bone and Rheumatic Disorders in Diabetes
Grey, A. B., & Dalbeth, N. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch53
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-22102-6.00004-4
An update on the role of antihyperglycemic agents in diabetoporosis
Sharma, N., & Nayak, A. K. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_35_23
Fracturas vertebrales en mujeres adultas con diabetes mellitus tipo 2
Stieben, L. A. R., Dobry, R., González, A. L., Anca, L., Bayo, S., López, M. I., SANCHEZ, A., & Brance, M. L. (2024) · Actualizaciones en osteología
Metadata
- Authors
- Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G.
- Affiliations
- Helen Hayes Hospital (US)
- Takeda (United States) (US)
- Corresponding author
- Bone, Henry G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4691-4701
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2085155826
- Cited by
- 47
- References
- 53
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 2
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Takeda Pharmaceuticals North America
- Takeda Pharmaceuticals International
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- thiazolidinediones, bone mineral density, bone turnover, postmenopausal women, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, fracture, glycemic control, insulin sensitivity, fat mass, lumbar spine
- MeSH terms
- Pioglitazone, Aged, Bone and Bones, Bone Resorption, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Middle Aged, Prediabetic State, Biomarkers, Bone Density, Bone Remodeling, Postmenopause, Glucose Intolerance, Thiazolidinediones, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.